PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced ...
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
7 Nov 2019
Analysis of assay used in IMpassion130 to guide treatment of metastatic and adva...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Analysis of assay used in IMpassion130 to guide treatment of metastatic and advanced breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
31 Oct 2019
Using aspirin for cancer prevention
Prof Ruth Langley - University College London, London, UK
Using aspirin for cancer prevention ( Prof Ruth Langley - University College London, London, UK )
24 Oct 2019
Shaping the future of metastasis - ecancer investigates
Monique Biryiana - ecancer Medical Reporter, Dr Chris Bakal - Dynamical Cell Sys...
Shaping the future of metastasis - ecancer investigates ( Monique Biryiana - ecancer Medical Reporter, Dr Chris Bakal - Dynamical Cell Systems Team Leader, Patricia Pascual Vargas - PhD Student )
14 Oct 2019
Comment: Critical quality attributes of biosimilars
Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Comment: Critical quality attributes of biosimilars ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )
8 Oct 2019
Simplifying molecular subtypes of metastatic gastric cancer
Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain
Simplifying molecular subtypes of metastatic gastric cancer ( Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain )
8 Oct 2019
VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer
Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany
VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer ( Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )
7 Oct 2019
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resist...
Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer ( Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands )
7 Oct 2019
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer ( Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain )
7 Oct 2019
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanom...
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
7 Oct 2019
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Dr Jonathan Ledermann - University College Hospital, London, UK
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma ( Dr Jonathan Ledermann - University College Hospital, London, UK )
7 Oct 2019
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
7 Oct 2019